Gamma Medica Honors Milestone Year for Groundbreaking MBI Breast Cancer Detection Solution at RSNA 2016

2016 clinical evidence confirms that adding LumaGEM®Molecular
Breast Imaging (MBI) to mammography as a secondary screening method is
more than twice as effective as mammogram and ultrasound in detecting
cancer for women with dense breast tissue

CHICAGO–(BUSINESS WIRE)–Gamma
Medica
, a leader in molecular breast imaging (MBI) technology, today
announced several 2016 achievements for its LumaGEM
Molecular Breast Imaging
system at this year’s Radiological Society
of North America (RSNA) annual meeting (booth #2871). Over the past
year, this MBI system has grown in national prominence and expanded its
user base through a major educational campaign on breast density called Be
Certain
and by driving irrefutable clinical results featured in a breakthrough
clinical study
.

Specifically, Gamma Medica delivered critical attention to the issue of
breast density in cancer screenings through the following:

  • Spearheading the educational Be
    Certain
    campaign to educate women about dense breast tissue and
    secondary screening options
  • LumaGEM was featured in a breakthrough
    clinical study
    that proved the benefits of MBI vs. mammograms for
    women with dense breasts (nearly 50 percent of U.S. women)
  • Announced high-profile installations at medical centers nationwide,
    including Henry Ford Health System (Michigan), Mayo Clinic Health
    System (Minnesota, Arizona and Florida locations)
  • MBI’s benefits were featured in the national media, including NBC
    Nightly News with Lester Holt
    , Glamour
    Magazine
    , WEtv
    and major trade magazines, including Becker’s
    Hospital Review
    and Radiology
    Today
    , before, during and following Breast Cancer Awareness Month

“This year’s clinical reinforcement combined with our partnerships with
major health systems and expanding share of voice collectively
underscore how we are spreading critically needed awareness not just
about breast density in general, but about LumaGEM MBI,” said Philip
Croxford, Gamma Medica president and CEO. “Through creating this
awareness, we are giving more women access to the most advanced and
accurate breast screening tool available for all breast tissue types,
enabling them to personalize their health care and allowing earlier
detection and better outcomes when cancer is found.”

Breast cancer is one of the leading causes of death in women, with
40,000 annual breast cancer deaths in the U.S. alone. Almost 50 percent
of women in the U.S. are diagnosed with dense breast tissue.
Unfortunately, not only do many not realize they have dense breasts, but
they may not understand what it means for their risk of breast cancer.
There may be cases where a woman with dense breasts received a negative
mammogram, however she is later diagnosed with breast cancer. Dense
breast tissue and cancer both appear white on mammograms, sometimes
making it difficult to distinguish between the two. This can lead to
false negatives or delayed diagnoses.

The LumaGEM is a proven
imaging modality
that will improve early and accurate breast cancer
detection for women who face a greater risk of missed detection in
mammograms and other screening modalities. Recent studies have confirmed
that MBI highlights metabolic activity in breast tumors not visible on
mammograms due to tissue density, leading to earlier diagnosis. Clinical
research also shows use of LumaGEM reduces biopsies, often painful and
costly, by 50 percent compared to other modalities. A breakthrough
retrospective study
, involving over 1,700 women with dense breast
tissue over a three year period, was published in the American Journal
of Roentgenology’s August issue confirmed LumaGEM’s high incremental
cancer detection rate of 7.7 cancers per thousand (7.7/1000), this
compares with published data for primary mammography screening alone of
3/1000. The study also concluded that – when MBI was used as a secondary
screening modality – the total number of cancers found was approximately
12/1000. Approximately 85 percent of these cancers were also confirmed
as invasive and node negative, indicating they were detected at an early
stage and therefore presented a better prognosis.

To educate women this year about the importance of MBI and breast
density, Gamma Medica launched the Be
Certain
campaign, which aims to give physicians and women access to
the most accurate clinical information on breast density and breast
cancer detection. In addition to education, Gamma Medica is committed to
increasing the number of accurate early breast cancer screenings through
installations at major facilities like Henry Ford. Every woman deserves
to Be Certain about her breast health and have access to the latest
diagnostic tools to help reduce late diagnosis and improve patient
clinical outcomes.

About Gamma Medica, Inc.
Gamma Medica, Inc. is a women’s
health company focused on overcoming the limitations of anatomical
imaging experienced by mammography and other screening modalities in the
early detection of breast cancer. The company’s LumaGEM® MBI system is
the first commercially available, FDA-cleared, fully solid-state digital
imaging system utilizing dual-head Digital Direct Conversion Gamma
Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90
percent sensitivity and specificity, LumaGEM MBI has been shown to
significantly improve cancer detection in women with dense breast tissue
with fewer false positives relative to anatomical imaging technologies,
such as MRI and whole breast ultrasound. For more information visit, www.gammamedica.com.

Contacts

Media Contact
Racepoint Global
Tara Kadioglu,
617-624-3239
tkadioglu@racepointglobal.com